Immunocore gets EU nod for TCR cancer therapy Kimmtrak
pharmaphorum
APRIL 5, 2022
Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised.
Let's personalize your content